Rucaparib, known by its brand name Rubraca®, is currently owned and made by pharmaand GmbH (pharma&).
Pharmaand GmbH is responsible for the manufacturing and distribution of Rubraca® tablets, an oral poly(ADP-ribose) polymerase (PARP) inhibitor used in the treatment of certain cancers. This ownership transfer ensures the continued availability and development of this important medication for patients.
Understanding Rucaparib
Rucaparib is a targeted therapy that works by inhibiting PARP enzymes, which are involved in DNA repair. By blocking these enzymes, rucaparib can prevent cancer cells with specific DNA repair deficiencies from repairing their damaged DNA, leading to cell death. It is primarily used for the treatment of certain types of ovarian cancer.
Key Information
To provide a clear overview of the current manufacturer:
| Aspect | Detail |
|---|---|
| Drug Name | Rucaparib |
| Brand Name | Rubraca® |
| Manufacturer | pharmaand GmbH (pharma&) |
| Type | Poly(ADP-ribose) Polymerase (PARP) inhibitor |
For more detailed information regarding the product, including prescribing information and patient resources, you can visit the official Rubraca® website: www.rubraca.com.
